Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

ImmunoGen Inc Announces Discontinuation of IMGN901 Study in Small-Cell Lung Cancer (SCLC)


Tuesday, 5 Nov 2013 06:31am EST 

ImmunoGen Inc announced the decision to stop the IMGN901 Phase II SCLC study, following the recommendation of the trial`s independent Data Monitoring Committee (DMC). ImmunoGen is in the process of updating study investigators and regulatory authorities. IMGN901 is a CD56-targeting ADC. 

Company Quote

11.89
0.1 +0.85%
4:00pm EDT